ACTIVE SESSION TAPE Equities Quant: HOLD

Why Is DRTSW (DRTSW) Stock Up Today?

Updated Nov 21, 2026 6:51 PM ET ยท Prev Close $1.54

Pro Workspace
Last Session Price
$1.61 +4.55%
+$0.07 vs $1.54 prior close
Intraday Range
$1.28 โ€“ $1.90
Open $1.28
Relative Volume
0.81x Avg
45,081 sh
52-Week Range
$0.28 โ€“ $4.62
Benchmark Alpha
+8.19% vs SPY
+10.22% vs QQQ
20-Session Trend -46.3%

Session Regime & Catalyst Assessment

68% Signal Conviction
TECHNICAL 68% Driver Weight

Drtsw Advancing 4.55% on 0.81x Relative Volume

Drtsw (Drtsw) is advancing 4.55% (+$0.07) to $1.61 on 0.81x average session volume. Relative to benchmarks, DRTSW is outperforming the S&P 500 by +8.19%. 14-day RSI stands at 30.6, keeping momentum in a bearish regime.

NEWS 70% Weight
Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update

- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the Sno 2026 Annual Meeting all eight treated patients alive, with median overall survival not reached, and a 100 objective response ra

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($1.61) trades relative to 20-day SMA ($2.81) and 50-day SMA ($3.40).

Volume Confirmation
LOW VOLUME (0.81x) Consolidation
Sub-average participation โ€” monitor RVOL expansion above 1.2x.
Composite Catalyst Confidence 68%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

DRTSW outperforming the S&P 500 by +8.19%
DRTSW Session
+4.55%
$1.61
S&P 500 (SPY)
-3.64%
$689.81
Nasdaq 100 (QQQ)
-5.67%
$608.45
Alpha vs SPY: +8.19% Alpha vs QQQ: +10.22%

Recent DRTSW Catalyst Headlines

Verified Wire
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100 Orr, 100 Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8 30am ET November 16

- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026 median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment range 3.1 to 11.6 mont

Yahoo Finance ยท Nov 15, 2026

1โ€“3 Day Expected Range & Key Level

48% Follow-Through
Lower Bound
$1.52
Short-term support band
Upper Bound
$1.70
Short-term resistance band
Key Inflection Level
$1.90 (session resistance)

Monitor volume expansion above 1.5x RVOL around $1.90 (session resistance) for directional breakout confirmation.

Technical Regime (DRTSW)

BEARISH MA TREND
RSI (14)
30.6
Bearish
20-Day SMA
$2.81
Below 20d
50-Day SMA
$3.40
Below 50d
MACD Signal
Bearish
MACD -0.46
ADX (14)
26.1
Strong trend
10d Momentum
-1.67
Soft 10-day momentum

Retail & Crowd Sentiment

Neutral
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Reddit communities: 1 comment (Neutral)

About DRTSW

Sector
Equities

Get Instant DRTSW Catalyst Alerts

Receive an email alert when DRTSW triggers an unusual volume breakout, options sweep, or rating shift.

DRTSW Session & Catalyst FAQ

Why is DRTSW stock up today?

Drtsw (Drtsw) is advancing 4.55% (+$0.07) to $1.61 on 0.81x average session volume. Relative to benchmarks, DRTSW is outperforming the S&P 500 by +8.19%. 14-day RSI stands at 30.6, keeping momentum in a bearish regime.

Is DRTSW stock a buy or sell right now?

Today's session carries a 68% catalyst conviction score on 0.81x relative volume (low participation). Our multi-factor model currently rates DRTSW as HOLD. Review full valuation, quality, and timing signals on the DRTSW Buy or Sell Decision Brief โ†’

What is DRTSW's intrinsic value and expected trading range?

At $1.61, DRTSW's modeled 1-to-3 session range is $1.52 โ€“ $1.70, with a key inflection level at $1.90 (session resistance). Compare current price against multi-year cash flow projections in the DRTSW Intrinsic Value & DCF Model โ†’ and Market Cycle Phase Tracker โ†’

What do RSI and moving averages signal for DRTSW?

RSI at 30.6 reflects soft below-midline momentum. DRTSW trades at $1.61 relative to its 20-day SMA ($2.81) and 50-day SMA ($3.40), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs